两组免疫抑制方案用于肾移植术后的对比研究  

Comparison of Two Immunosuppressive Schemes Used in Renal Rransplant Recipients

作　　者：唐波[1] 叶丽卡[1] 王若伦[1] 李伟[2] 许华佟[3] 

机构地区：[1]广州医学院第二附属医院药学部,广东广州510260 [2]武警广东总队医院,广东广州510000 [3]广东药学院,广东广州510006

出　　处：《今日药学》2009年第12期35-37,共3页Pharmacy Today

摘　　要：目的比较肾移植患者术后应用他克莫司(FK506)或环孢素A(CsA)为基础的2种免疫抑制方案的疗效和安全性。方法肾移植患者57例分成2组,FK506组为25例,CsA组为32例。观察肾移植后1年内两组的急性排斥发生率、药物性肝肾损害发生率、血糖异常及感染的发生情况。结果两组免疫抑制方案在肝肾损害发生率、感染发生率以及对血糖的影响方面差异无统计学意义。结论两种免疫抑制方案在肾移植术后具有同样的临床应用价值。Objective To compare the effect and safety of 2 elementary immunosuppressive schemes based on FK506 and CsA in patients after renal transplant. Methods A total of 57 cases of kidney transplant recipients were divided into 2 groups： Group A （n = 25） treated with FK506; Group B （n = 32） treated with CsA. The follow-up period was at least 1 year. The end-points of observation included acute rejection, and reversal rate of after immunosuppressive drugs bolus, hepatotoxicity, renal impairment, hyperglycosemia and infection rates in the 2 groups. Results Two immunosuppressive schemes make no difference in acute rejection, hepatotoxicity, renal impairment, hyperglycosemia and infection rates. Conclusion Two immunosuppressive schemes have the same value of clinical practice.

关 键 词：他克莫司 环孢素 肾移植 免疫抑制剂 

分 类 号：R979.5[医药卫生—药品]